261 related articles for article (PubMed ID: 35440669)
1. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
Umeh-Garcia M; O'Geen H; Simion C; Gephart MH; Segal DJ; Sweeney CA
Br J Cancer; 2022 Aug; 127(3):436-448. PubMed ID: 35440669
[TBL] [Abstract][Full Text] [Related]
2. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
[TBL] [Abstract][Full Text] [Related]
3. Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Bagu ET; Miah S; Dai C; Spriggs T; Ogunbolude Y; Beaton E; Sanders M; Goel RK; Bonham K; Lukong KE
Oncotarget; 2017 Feb; 8(7):11442-11459. PubMed ID: 28077797
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
6. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.
Choudhury SR; Cui Y; Lubecka K; Stefanska B; Irudayaraj J
Oncotarget; 2016 Jul; 7(29):46545-46556. PubMed ID: 27356740
[TBL] [Abstract][Full Text] [Related]
8. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
9. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
10. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
11. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
[TBL] [Abstract][Full Text] [Related]
13. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
[TBL] [Abstract][Full Text] [Related]
14. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
[TBL] [Abstract][Full Text] [Related]
15. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.
Augoff K; McCue B; Plow EF; Sossey-Alaoui K
Mol Cancer; 2012 Jan; 11():5. PubMed ID: 22289355
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
[TBL] [Abstract][Full Text] [Related]
17. Putative promoters within gene bodies control exon expression via TET1-mediated H3K36 methylation.
Ma L; Muhammad T; Wang H; Du G; Sakhawat A; Wei Y; Ali Khan A; Cong X; Huang Y
J Cell Physiol; 2020 Oct; 235(10):6711-6724. PubMed ID: 31994732
[TBL] [Abstract][Full Text] [Related]
18. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
19. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
